Accelerate Diagnostics reports Q4 EPS (89c), consensus (75c)

Reports Q4 revenue $3M, consensus $3.45M. The company said, “In 2023, we made significant progress with the development of our next-generation rapid Antibiotic Susceptibility Testing system, Accelerate Wave. We continue to advance this important development program and believe that we remain on plan to begin our clinical trials in the second quarter of 2024. In addition, we continue to expand and secure our Accelerate Pheno customer base, with an upgrade path to Wave adoption. Based on consistent customer feedback, Accelerate Wave is anticipated to set the new standard for rapid, same-shift, susceptibility testing.”